Publication | Closed Access

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

Lux-lung 3Lux-lung 6MedicinePathologyBronchial NeoplasmMolecular OncologyCancer TreatmentOncologyRadiation OncologyLung CancerCancer ResearchPhase 3